Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) FCF Margin (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of FCF Margin data on record, last reported at 1515.32% in Q4 2025.

  • For Q4 2025, FCF Margin changed N/A year-over-year to 1515.32%; the TTM value through Dec 2025 reached 4985.5%, up 1718717.0%, while the annual FY2025 figure was 4985.5%, 1718717.0% up from the prior year.
  • FCF Margin reached 1515.32% in Q4 2025 per CRNX's latest filing, up from 81073.43% in the prior quarter.
  • Across five years, FCF Margin topped out at 435.32% in Q1 2022 and bottomed at 81073.43% in Q3 2025.
  • Average FCF Margin over 5 years is 12635.7%, with a median of 7387.05% recorded in 2022.
  • The widest YoY moves for FCF Margin: up 416213bps in 2025, down -1629007bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 2097.5% in 2021, then plummeted by -147bps to 5190.83% in 2022, then tumbled by -131bps to 11997.98% in 2023, then fell by -4bps to 12471.93% in 2024, then surged by 88bps to 1515.32% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 1515.32% in Q4 2025, 81073.43% in Q3 2025, and 8309.8% in Q2 2025.